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In Madagascar, dog-mediated rabies has been endemic for over a century, however there is little data on
its incidence or impact. We collected data over a 16-month period on provisioning of post-exposure pro-
phylaxis (PEP) at a focal clinic in the Moramanga District and determined the rabies status of biting ani-
mals using clinical and laboratory diagnosis. We find that animal rabies cases are widespread, and clinic-
based triage and investigation are effective ways to increase detection of rabies exposures and to rule out
non-cases. A high proportion of rabies-exposed persons from Moramanga sought (84%) and completed
PEP (90% of those that initiated PEP), likely reflecting the access and free provisioning of PEP in the dis-
trict. Current clinic vial sharing practices demonstrate the potential for intradermal administration of PEP
in endemic African settings, reducing vaccine use by 50% in comparison to intramuscular administration.
A high proportion of PEP demand was attributed to rabies cases, with approximately 20% of PEP admin-
istered to probable rabies exposures and an additional 20% to low-to-no risk contacts with confirmed/
probable animal or human cases. Using a simplified decision tree and our data on rabies exposure status
and health-seeking behavior, we estimated an annual incidence of 42–110 rabies exposures and 1–3
deaths per 100,000 persons annually. Extrapolating to Madagascar, we estimate an annual burden of
282–745 human rabies deaths with current PEP provisioning averting 1499–3958 deaths each year.
Data from other clinics and districts are needed to improve these estimates, particularly given that PEP
availability is currently limited to only 31 clinics in the country. A combined strategy of mass dog vacci-
nation, enhanced surveillance, and expanded access to PEP along with more judicious guidelines for
administration could effectively reduce and eventually eliminate the burden of rabies in Madagascar.
 2018 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
To date, canine rabies is estimated to cause around 60,000
human deaths annually [1]. Infection is completely preventable if
exposed individuals receive prompt post-exposure prophylaxis(PEP), but most human cases occur in low-income countries in
Africa and Asia, where access to PEP is often limited [2]. Mass
dog vaccination has proved effective in preventing human rabies
in many countries [3]. The WHO and their partners have set a tar-
get for an end to human deaths due to dog-mediated rabies by the
year 2030 [4]. This goal will require delivering vaccine interven-
tions in both domestic dog and human populations in resource-
limited settings where canine rabies remains endemic.tion of
2 M. Rajeev et al. / Vaccine xxx (xxxx) xxxIn Madagascar, the first human rabies case was reported in
1896. The Institut Pasteur de Madagascar (IPM) has provided PEP
free-of-charge to patients in the country since 1902 [5]. Until
2006, IPM provided rabies nerve-tissue vaccines to all district
health centers. In 2006, use of nerve tissue was discontinued in
the country, and shifted to use of the Purified Vero Cell Rabies Vac-
cine solely, but with provisioning to only a subset of district health
centers [6]. Currently, there are 31 anti-rabies medical centers
(ARMC, also referred to as Centre de Traitement Antirabique)
across the country. Each ARMC is located in a public hospital or
health care center, and there are no other sources of PEP available
publicly or privately in the country. At the time of the study, all
ARMC were using the modified Thai Red Cross (TRC) protocol (i.e.
2 intradermal injections of 0.1 mL at two sites, deltoids and/or
thighs, on days 0, 3, 7 and 28). Purified equine rabies immunoglob-
ulin (RIG) is only available at the IPM ARMC in the capital city
Antananarivo, and patients from peripheral ARMC are supposed
to be referred to the capital when RIG is necessary. Both vaccine
and RIG are administered free-of-charge to patients. Culling is
the official policy to respond to any suspected or confirmed animal
rabies case (Decret No. 95-375, 1995) and dog vaccines are limited
in availability and only at a high cost to owners.
As rabies control in the dog population is minimal and ad hoc,
and PEP availability is limited to the 31 ARMCs, there is likely a sig-
nificant burden of rabies in Madagascar. The National Rabies Refer-
ence Laboratory (NRRL) at IPM in Antananarivo is the only facility
with the capacity for rabies diagnostic testing [5] and most of the
samples submitted to the laboratory come from the capital city and
surrounding peri-urban areas. Even with this limited surveillance,
62% of submitted animal samples tested positive for rabies
between 2010 and 2015 [7], with cases of canine rabies having
been recorded in 38 out of the 114 districts in the country [6].
Annually, between 4 and 10 human rabies cases and 21-111 ani-
mal rabies cases are laboratory confirmed [7], but underreporting
of both human and animal cases is likely substantial.
To better understand the burden of rabies in Madagascar and
PEP functioning in this context, we collected data on reported ani-
mal bites and vaccine provisioning at the ARMC in the Moramanga
District over a 16-month period (Sep 2016–Dec 2017). We fol-
lowed up on bite patients to assess the rabies status of biting ani-
mals through clinical and laboratory diagnosis and contact tracing
to identify unreported exposures. Using the resulting estimates of
health seeking behavior, PEP provisioning and adherence, and the
incidence of rabies exposures, we applied a simplified decision tree
to estimate the number of deaths averted and the current burden
of human rabies in the Moramanga District and extrapolate this
across Madagascar.2. Methods
2.1. Study site
The Moramanga District is located mid-way between the cen-
tral highlands and the east coast of Madagascar, at an average alti-
tude of 936 m. It comprises 21 communes, covering approximately
7150 km2 with a human population between 300,000–350,000
people (www.worldpop.org, [8]). The Moramanga ARMC is located
in the Emergency Room (ER) of the District Hospital. The clinic uses
0.5 mL vials of Verorab (Sanofi Pasteur) anti-rabies human vaccine
provided through IPM. Generally, if a vial is opened, it is used
within one working day. The ER staff requests that patients report
between 9 AM–2 PM for PEP to facilitate vial sharing, with one vial
split between two patients. Whether animal bites are treated as
emergencies and given PEP after these hours depends on the on-
call physician. Patients first reporting to other public or privatePlease cite this article as: M. Rajeev, G. Edosoa, C. Hanitriniaina et al., Healthcar
human rabies burden in Madagascar, Vaccine, https://doi.org/10.1016/j.vaccinhospitals depend on clinician referral to report to the ARMC. The
nearest other health facility offering PEP is the IPM ARMC in
Antananarivo, which is a minimum of 2–3 h travel time from any-
where in the district. Patients requiring RIG are referred to IPM.
2.2. Data and analyses
From September 2016 to December 2017, we collected baseline
data from clinic registers on PEP administration and patient
throughput, including patient demographics. The clinic does not
track vial use, so we calculated a conservative minimum estimate
of vaccine waste (i.e. not accounting for errors in administration,
breakage etc.), based on incomplete vial sharing. Current practice
is for a single 0.5 mL vial to be split between two patients, with
each receiving 0.2 mL of vaccine (2  0.1 mL injections/visit), and
the remaining 0.1 mL of vaccine considered wastage. We assumed
a further 0.2 mL is wasted on each day with an odd number of
patient presentations (for vials used only by one patient, with
the remaining 0.3 mL discarded). We also calculated the minimum
estimate of vials required and wastage under alternative scenarios:
with 5  0.1 mL injections obtained per 0.5 mL vial; adopting the
newly recommended abridged 1-week ID regimen administered
on day 0, 3, and 7; and adopting these two practices in combina-
tion. We compared these scenarios to the minimum number of
vials necessary given intramuscular (IM) administration (Essen 4-
dose or Zagreb) with one vial used per injection and assuming no
change in compliance.
For all patients, the clinic collects data on the biting animal spe-
cies and compliance to PEP, but not on which patients are referred
and/or receive RIG.We used data frompatientswhowere either bit-
ten or resided in Moramanga that reported to the IPM ARMC during
this period to identify those that received RIG, although we did not
have data for howmanywere referred in total. For a subset of biting
animals, samples were collected either by local veterinary surveil-
lance officers submitting the whole head or animal for testing) or
using the strawmethod for brain tissue collection [9]. Sampleswere
sent to the NRRL at IPM for diagnostic confirmation using the fluo-
rescent antibody test (FAT). Probable human rabies caseswere iden-
tified from patients who presented to the clinic with neurological
signs, hadahistoryof ananimal bite, anddied shortly after, or deaths
reported to thedistricthealthofficealsowith consistenthistory.One
suspect human casewas confirmed (positive RT-PCR result on a skin
biopsy from the neck [10]).
We interviewed as many patients as possible to classify their
rabies exposure status. We classified animals and people (in terms
of their exposure to rabies), according to the following case
definitions:
 Confirmed case/exposure: an animal or human that tested pos-
itive (by FAT or RT-PCR, respectively) for rabies/a person bitten
or scratched by an animal that tested positive for rabies.
 Probable case/exposure: an animal or human that was classi-
fied as probable for rabies/a person who was bitten or scratched
by an animal that was classified as probable for rabies based on
adapting the six-step method, with probable cases defined as
showing at least one clinical sign and dying or disappearing
within 10 days of the bite [11].
 Contact with a confirmed/probable rabies case: any person in
contact with a confirmed/probable human or animal rabies case
as defined by the current national guidelines for ARMCs:
– Touching the mouth or saliva, or sharing food and drink
(human case).
– Manipulating the body or helping to bury (human case).
– Licks or contact with the saliva 15 days preceding death
(human or animal case).
– Taking a sample from a suspect animal or human case.e utilization, provisioning of post-exposure prophylaxis, and estimation of
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recorded at the clinic.
 Non-case/non-exposure: an animal that was determined to not
be rabid/ a person who was bitten or scratched by an animal
that was determined to not be rabid (i.e. an animal that
remained alive 10 days after the bite or tested negative).
 Unknown case/exposure: an animal/patient for whom we
were unable to assign a status to, either due to ambiguity in
the case history or who, despite attempts via phone call or
household visit, we were unable to locate.
For patients reporting between Sep 2016–July 2017, we verified
the status of the animal retrospectively through phone interviews
or household visits. From August 2017 until December 2017, we
interviewed patients directly at the clinic and triaged patients for
follow-up, only conducting household visits for cases assigned as
probable rabies or for those we were unable to interview at the
clinic. Household visits were also limited by accessibility due to
road conditions.
We adapted established decision tree frameworks [1,12] to esti-
mate the burden of human rabies and deaths averted through use
of PEP using parameters derived from these data. We assumed that
no deaths resulted from incomplete or delayed PEP, including the
absence of RIG, and that all people who report to an ARMC receive
PEP, i.e. no shortages or vaccine refusal. We excluded contacts with
(rather than exposures to - see case definitions above) confirmed/
probable cases from this analysis, as these pose minimal to no risk
of infection [13]. We calculated human rabies deaths and deaths
averted by PEP according to the decision tree described in Fig. 1,
where prabid is the proportion of reported bites that are considered
rabies exposures (due to confirmed/probable rabid animals), preport
is the proportion of rabies exposures that present to an ARMC, and
pinfect is the probability of infection, and thus death, given a rabiesBites
Rabies 
exposures
prabid
1 - prabid
1 - prepor
preport
Non-exposures
Fig. 1. Adapted decision tree framework to estimate burden of human rabies deaths an
population (expected bites annually, dark red box) are genuine rabies exposures (Bites 
to rabies deaths or averted deaths. Of the genuine rabies exposures, a fraction present to
exposures). Some of these exposed persons would otherwise have become infected and
PEP). Of the unreported exposures, a proportion will die due to rabies infection (Unreport
colour in this figure legend, the reader is referred to the web version of this article.)
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human rabies burden in Madagascar, Vaccine, https://doi.org/10.1016/j.vaccinexposure [14]. We calculated an annual bite incidence in the dis-
trict by taking the average monthly bites per 100,000 recorded in
our data during the period of systematic triage (Aug 2017–Dec
2017) and multiplying by 12. Population estimates were taken as
the midpoint between 2015 and 2020 UN adjusted population pro-
jections from World Pop (www.worldpop.org, [8]). All data were
collected using tablets (Samsung Tab 4 and Tab A) using forms
from the Wise Monkey Portal ((http://www.wisemonkeyfounda-
tion.org/) and the Device Magic application (https://www.de-
vicemagic.com), and associated data were submitted and stored
in secure cloud-based servers. All data analysis and figures were
done in R (version 3.5.0, R Core Team, 2018).
2.3. Ethics statement
This research was approved by the Princeton University IRB (#
7801) and the Ministry of Public Health Ethics Committee (# 105-
MSANP/CE). Oral informed consent was obtained from all inter-
viewed participants. Sample collection from animal carcasses
was approved through the Princeton University Institutional
Biosafety Committee (# 1105-16) and the Animal Use and Care
Committee (# 2079A-16).3. Results
3.1. PEP provisioning at the clinic
Between September 2016–December 2017, a total of 1019
patients reported to the ARMC. Multiple patients were likely to
present on a given day, with only 3% of days where a single patient
reported. On average, 7 patients presented per day, but this distri-
bution was skewed with 10 or more patients reporting on 22% of
days, and zero patients on only 7% of days (Fig. 2A). Using the
updated TRC regimen, an estimated 1927 vials (of 0.5 mL) wereDeaths due to 
rabies
Exposures not 
resulting in 
death
Unreported 
exposures
t
pinfect
1 - pinfect
Deaths averted 
by PEP
Exposures not 
resulting in 
death
pinfect
1 - pinfect
Reported 
exposures
d deaths averted by PEP. We considered that some proportion of total bites in the
prabid = Rabies exposures), and non-exposures ((1  prabid)  Bites) do not contribute
an ARMC and all of these persons receive PEP (Rabies exposures  preport = Reported
died if they had not received PEP (Reported exposures  pinfect = Deaths averted by
ed exposures  pinfect = Deaths due to rabies). (For interpretation of the references to
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Fig. 2. PEP administration and vaccine use. (A) Distribution of observed daily patient presentations (i.e. the number of days with N patients reporting to the ARMC) and (B)
calculation of the minimum volume of vaccine (mL) used under current practice with PEP administered according to the updated TRC regimen or according to the latest WHO
recommendations with the abridged 1-week ID regimen. Use of 4  0.1 mL per 0.5 mL vial (current practice) vs. 5  0.1 mL injections per 0.5 mL vial were also compared. The
red dashed line corresponds to vaccine use under IM administration, assuming 1 vial per IM injection and the same level of compliance (i.e. under the Essen 4-dose or Zagreb
regimen). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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throughput of ARMC patients. Current ID administration requires
approximately 50% less vaccine vials compared to an IM regimen
(3597 vials) (Fig. 2B). Use of the abridged 1-week ID regimen could
reduce vial use by 20% and drawing 5  0.1 mL injections per vial
rather than 4 would further reduce vial use by up to 31%. In gen-
eral, extracting 5  0.1 mL injections from a vial reduces the vol-
ume of vaccine wasted by 40–50% (Fig. 2B).3.2. Rabies status and characteristics of biting animals
Of the 704 biting animals that were identified at the clinic and
through contact tracing, domestic dogs made up the majority
(87.5%), followed by cats (9%). Other species (<4% of biting animals)
included cows, rodents, one lemur, and one bat. The majority were
owned animals (56.7%). We followed up on 390/704 of these ani-
mals and identified that 67 were probable cases and 19 were con-
firmed cases, responsible respectively for 88 probable and 32
confirmed human exposures (Table 1, Fig. 3). Almost all of these
confirmed/probable rabid animals were domestic dogs (76/87).
Rabies was widespread, with confirmed/probable cases detected
in 14/21 communes in the Moramanga District (Fig. 3A). In addi-
tion, there was at least one confirmed case in 11/16 months and
at least one probable or confirmed case detected in each month
of the study. There were also 4 human cases (1 confirmed, 3 prob-
able) reported in the district during this period (Fig. 3B).
Amongst probable and confirmed animal rabies cases, unpro-
voked aggression was the most common clinical sign followed by
excessive salivation; other clinical signs were observed less fre-
quently (<15% of probable/confirmed cases). Confirmed and prob-
able animal cases were more frequently involved in biting
multiple people (42.5%) than non-cases (5.4%). They also more fre-
quently bit several animals. In contrast, provoked bites were twice
as common amongst non-cases (Table 1). Generally, clinical signs
were noted for both non-cases and probable cases, and bites from
a probable animal could also be classified as provoked based on our
criteria (so could not be used to rule out rabies). A source of infec-
tion was only identified for nine confirmed or probable cases (i.e.
either an observed bite or signs of a bite prior to biting or the onset
of clinical signs). Owners or community members rarely observed
when rabid animals bit other animals.Please cite this article as: M. Rajeev, G. Edosoa, C. Hanitriniaina et al., Healthcar
human rabies burden in Madagascar, Vaccine, https://doi.org/10.1016/j.vaccinMostprobable or confirmed rabid animalswerekilled after biting
or attempting to bite people or other animals (42.5%), or died from
disease (26.4%) or other causes (10.3%, including being hit by car,
poisoned, or dying from injuries). The remaining 18.6% disappeared
after the bite. The majority of animals classified as non-cases were
alive 10 days after the bite (94.4%), but three animals that were
not alive within 10 days of the bite subsequently tested negative,
and eight died at a later date (>10 days after the bite, Table 1).
Of the animalswe investigated, 20.5%were reported tohavebeen
placed in veterinary observation. Seven of these 80 observed ani-
mals were considered to be probable rabies cases by the veterinar-
ian. However, we did encounter two cases where the veterinary
conclusion differed from our case determination (one probable case
thatwas declared a non-case by the veterinary officer due to the age
of the animal, i.e. <3 months, and the other thatwas alive at the time
of our investigation approximately 3 months after the bite case,
whichwas declared a suspected rabies case by the veterinary officer
at the time of the visit). 17% of the animals we investigated were
reported to be vaccinated, with 29.2% of non-cases and 28.7% of
those placed in veterinary observation reported to be vaccinated.
No probable or confirmed animals had a history of vaccination.
3.3. Exposure status, health-seeking behavior, and PEP compliance of
bite victims and patients reporting to the ARMC
Of the 1019 patients presenting toMoramanga AMRC, 1.5%were
in transit andonly completed a subset of doses at the clinic. A further
6.8% came from outside of the district but completed their PEP
course inMoramanga; thesemostly came from the neighboring dis-
trict of Anosibe An’Ala (41/63), which does not have an ARMC and is
a minimum of 12 h travel time from the Moramanga ARMC. Twelve
patients were bitten outside the District, but resided in Moramanga
and completed their PEP course at the ARMC. We excluded patients
bitten in other districts from further analyses.
Excluding contacts with a confirmed/probable case (N = 197),
we were able to classify the status of 41.1% of human exposures
over this 16 month period, however this proportion varied over
time. By conducting clinic-based triage, we were able to classify
double the proportion of bite patients to a known exposure status
(27.4% of patients pre-August 2017 vs. 61.4% post-August 2017,
Fig. 4A). Of the 399 patients we followed up with, we were unable
to assign an exposure status to 25.8% (i.e. ‘Unknown’).e utilization, provisioning of post-exposure prophylaxis, and estimation of
e.2018.11.011
Table 1
Characteristics of biting animals as recorded from follow-up investigations.
Confirmed (%) Probable (%) Unknown (%) Non-case (%)
Total 19 68 108 195
Species Cat 3 (15.8) 2 (2.9) 9 (8.3) 21 (10.8)
Dog 15 (78.9) 61 (89.7) 91 (84.3) 173 (88.7)
Bovine 1 (5.3) 5 (7.4) 0 (0) 1 (0.5)
Rodent 0 (0) 0 (0) 6 (5.6) 0 (0)
Owned animal 16 (84.2) 42 (61.8) 30 (27.8) 189 (96.9)
Vaccinated 0 (0) 0 (0) 9 (8.3) 57 (29.2)
Veterinary observation 3 (15.8) 5 (7.4) 4 (3.7) 68 (34.9)
Outcome Alive 0 (0) 0 (0) 14 (13) 186 (95.4)
Disappeared or unknown 0 (0) 17 (25) 81 (75) 0 (0)
Died due to disease 4 (21.1) 19 (27.9) 0 (0) 1 (0.5)
Killed after biting a person/animal 14 (73.7) 23 (33.8) 4 (3.7) 2 (1)
Other cause of death 0 (0) 9 (13.2) 2 (1.9) 6 (3.1)
Clinical signs Bit multiple people 11 (57.9) 26 (38.2) 0 (0) 10 (5.1)
Bit other animals 5 (26.3) 10 (14.7) 1 (0.9) 0 (0)
Observed source of infection(i.e. signs of previous bite/observed bite) 4 (21.1) 5 (7.4) 2 (1.9) 2 (1)
Unprovoked aggression 12 (63.2) 47 (69.1) 41 (38) 33 (16.9)
Excess salivation 6 (31.6) 14 (20.6) 3 (2.8) 2 (1)
Hydrophobia 1 (5.3) 1 (1.5) 0 (0) 0 (0)
Lethargy 2 (10.5) 7 (10.3) 0 (0) 0 (0)
Paralysis 1 (5.3) 5 (7.4) 0 (0) 1 (0.5)
Vocalization 3 (15.8) 4 (5.9) 0 (0) 1 (0.5)
Restlessness 3 (15.8) 0 (0) 0 (0) 0 (0)
Hypersexuality 0 (0) 0 (0) 0 (0) 0 (0)
Running no reason 4 (21.1) 7 (10.3) 0 (0) 0 (0)
Strange movement 2 (10.5) 8 (11.8) 1 (0.9) 1 (0.5)
Provoked bite* 5 (26.3) 10 (14.7) 24 (22.2) 57 (29.2)
Average number of animals bitten 0.313 0.236 0.019 0
Average number of humans bitten 2.06 1.73 1 1.05
* With at least one indication of provocation (i.e. hitting or kicking the animal, interaction with food or object, playing or running, entering the house of the owner with a
guard dog, history of habitual aggression).
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sures and 1.5 days for confirmed exposures, with 61.1% of patients
reporting within 2 days of the exposure overall (Table 2). OverallPlease cite this article as: M. Rajeev, G. Edosoa, C. Hanitriniaina et al., Healthcar
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Table 2
Characteristics of all patients reporting for PEP and additional bite victims identified through contact tracing, including the type of exposure and health seeking behaviour.
Confirmed (%) Probable (%) Unknown (%) Non-exposure (%) Contact (%)
Total 35 85 425 202 197
Average age 23.5 23.8 23.7 25.5 30.7
Male 27 (77.1) 50 (58.8) 250 (58.8) 106 (52.5) 125 (63.5)
15 yrs or younger 19 (54.3) 39 (45.9) 189 (44.5) 84 (41.6) 46 (23.4)
Unreported 2 (5.7) 17 (20.0) 1 (0.2) 7 (3.5) –
Total reported 33 68 424 195 197
Completing at least 3 doses 29 (87.9) 63 (92.6) 383 (90.3) 170 (87.2) 178 (90.4)
Completing at least 4 doses 29 (87.9) 56 (82.4) 316 (74.5) 129 (66.2) 157 (79.7)
Completing more than 4 doses 1 (3) 3 (4.4) 8 (1.9) 3 (1.5) 1 (0.5)
Average delay between exposure and
reporting (days)
1.5 2.8 2.6 1.8 NA
Reported within 2 days of bite 28 (84.8) 48 (70.6) 324 (76.4) 159 (81.5) –
Interviewed 35 (1 0 0) 82 (96.5) 111 (26.1) 171 (84.7) –
Reported to peripheral clinic before
reporting to the ARMC
0 (0) 6 (7.3) 15 (13.5) 21 (12.3) –
Reported to a peripheral clinic only
(unreported to ARMC)
0 (0) 7 (8.5) 0 (0) 3 (1.8) –
Reported to any other hospital 0 (0) 13 (15.9) 15 (13.5) 24 (14) –
Wound location** Legs 8 (22.9) 31 (37.8) 51 (45.9) 79 (46.2) –
Feet 4 (11.4) 15 (18.3) 26 (23.4) 26 (15.2) –
Arms 9 (25.7) 5 (6.1) 6 (5.4) 14 (8.2) –
Hands 8 (22.9) 23 (28) 23 (20.7) 24 (14) –
Upper body 5 (14.3) 4 (4.9) 7 (6.3) 24 (14) –
Head or neck 2 (5.7) 4 (4.9) 1 (0.9) 6 (3.5) –
Wound type** Skin broken 21 (60) 57 (69.5) 92 (82.9) 126 (73.7) –
Superficial 25 (71.4) 59 (72) 94 (84.7) 134 (78.4) –
Deep 2 (5.7) 5 (6.1) 6 (5.4) 10 (5.8) –
Scratch 8 (22.9) 15 (18.3) 18 (16.2) 32 (18.7) –
Bite 29 (82.9) 64 (78) 91 (82) 144 (84.2) –
Multiple 1 (2.9) 1 (1.2) 1 (0.9) 3 (1.8) –
Over clothes 7 (20) 9 (11) 31 (27.9) 45 (26.3) –
Washed wound 28 (80) 62 (75.6) 96 (86.5) 139 (81.3) –
Bold rows are denominators for subsequent rows.
** Categories are not mutually exclusive and were assigned as they applied to each bite victim.
6 M. Rajeev et al. / Vaccine xxx (xxxx) xxxclinic protocol was to restart the course if there was a delay
between PEP doses. Eighteen patients from the Moramanga Dis-
trict were recorded at IPM, and fourteen of these patients received
RIG (4 confirmed, 3 unknown, and 7 non-exposures).
A total of 201 patients reported as contacts with a probable
rabies case (human or animal), making up 20% of patients receiving
PEP. Fig. 4B shows the distributions of contacts per case, with con-
tacts with the four human cases comprising the majority of thesePlease cite this article as: M. Rajeev, G. Edosoa, C. Hanitriniaina et al., Healthcar
human rabies burden in Madagascar, Vaccine, https://doi.org/10.1016/j.vaccinpatients (41.6%). One bovine case, for which the contacts were peo-
ple that consumed the meat of the animal, subsequently tested
negative. In addition, details about the nature and timing of the
contact, and for a subset details on the probable animal itself (6
unknown cases), were not recorded at the clinic.
Overall, demographics of patients were skewed male (59.1%)
and 15 years of age or younger (39.9%), with almost 50% of proba-
ble/confirmed rabies exposures 15 years of age or younger com-e utilization, provisioning of post-exposure prophylaxis, and estimation of
e.2018.11.011
Table 3
Details of the human deaths in the district during the study period.
Case Age Sex Type of exposure Biting animal Health-seeking and wound response Time between bite
and death
Confirmed 3 F Superficial scratch
to the face
Owned dog, killed
after biting
Did not report to the CTAR or any other hospitals;
did not wash wound, but applied tambavy (a local plant).
2 months
Suspected 67 M Bite, no details on location Owned dog, disappeared
after the bite
No details but did not report for PEP. 1 month
Suspected 61 M Superficial bite
to the hands
Owned dog, killed
after biting
Reported to peripheral clinic and was referred to the CTAR,
but did not report for PEP; washed wound and applied oil.
2 months
Suspected 45 M Deep bite to the hands Unknown dog, disappeared
after the bite
Reported to peripheral clinic and was referred to the CTAR,
but did not report for PEP; washed wound.
1 year
M. Rajeev et al. / Vaccine xxx (xxxx) xxx 7pared to 37% of the population in that age group in Moramanga (R.
Ratovoson, unpublished data from the Health and Demographic
Surveillance System (HDSS) in 3 communes of Moramanga dis-
trict). For interviewed bite victims (N = 399), we also had data on
characteristics of the exposure and post-bite response. The major-
ity of wounds were superficial, but with skin broken. Bites to the
head or neck and non-superficial bite injuries made up a small
fraction of overall exposures (9%), and most wounds were
reported to be from bites vs. scratches. Overall, 81.4% of inter-
viewed bite victims reported washing the wound with soap and
water (Table 2). 13% of interviewees reported to peripheral clinics
before reporting to the ARMC, with 42 of these 52 patients report-
ing to a peripheral clinic before reporting for PEP at the ARMC and
the 10 remaining patients reporting only to a peripheral clinic (i.e.
did not report for PEP).
We identified a total of 27 people that did not seek PEP, 19 of
which were confirmed or probable rabies exposures, resulting in
four human deaths (details in Table 3). The remaining 23 were
identified during contact tracing investigations and were in good
health at the time of investigation; nine of these people reported
for PEP after the investigation (5 probable, 2 confirmed exposures,
2 non-exposures). Of the 17 people that reported a reason for not
seeking PEP, most were due to ignorance/misconceptions about
rabies (n = 9, including thinking the animal was too young to beTable 4
Parameters for decision tree model (note that exposures exclude contacts with
probable cases).
Parameter Value Description
Overall bite incidence per
100,000 people
189 12  average of monthly bites
(both unreported and
reported) between Aug and
Dec 2017, when systematic
triage was in place
Proportion of overall bites due
to rabid animals, prabid
0.22–0.58 The average monthly
proportion of
probable/confirmed
exposures only (lower limit)
or probable/confirmed AND
unknown exposures (upper
limit) between Aug and Dec
2017, when systematic triage
was in place.
Proportion of rabies exposures
that seek PEP, preport
0.84 The proportion of
probable/confirmed
exposures which reported to
the ARMC
Proportion of rabies exposures
that result in infection in
the absence of PEP, pinfect
0.164 Changalucha et al. 2018
(submitted) [12]
Moramanga population 328,000 Midpoint between World Pop
2015 and 2020 UN adjusted
population projections [8]
Madagascar population 26,017,000 Midpoint between World Pop
2015 and 2020 UN adjusted
population projections [8]
Please cite this article as: M. Rajeev, G. Edosoa, C. Hanitriniaina et al., Healthcar
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mission, reliance on traditional medicine, and complete ignorance
of PEP/rabies) and lack of funds to travel to the health center
(n = 8).3.4. Deaths averted and current burden of human rabies
We calculated an overall incidence of 189 bites per 100,000
people annually. Given this bite incidence and other parameters
(Table 4), we estimate between 19 and 50 deaths averted by PEP
and between 4 and 9 human rabies deaths in the Moramanga dis-
trict annually. Extrapolating to the population of Madagascar, we
estimate a current burden of 282–745 human rabies deaths annu-
ally, with PEP averting an additional 1499–3958 human rabies
deaths. Overall, we estimate a rabies exposure incidence of 42–
110 per 100,000 persons annually.4. Discussion
4.1. Key findings
Our results demonstrate that canine rabies is widespread in the
Moramanga District and results in a high incidence of human expo-
sures. Current free provisioning of PEP to patients is estimated to
prevent the majority of deaths resulting from these exposures. Fur-
thermore, clinic practice of ID administration of PEP uses half the
vaccine volume compared to IM administration and shows how
vial sharing practices can be implemented effectively in an ende-
mic setting in sub-Saharan Africa. Despite these successful prac-
tices, canine rabies is still responsible for a significant burden of
human deaths and drives high demand for PEP. The substantial
costs of procuring and provising free PEP are currently borne by
IPM, but would otherwise fall to Madagascar’s health system
and/or patients potentially leading to more human rabies deaths.
While approximately 20% of patients reporting for PEP were
classified as rabies exposures, an additional 20% were due to
low-to-no risk contacts with confirmed or probable animal and
human cases, many of which do not fit the WHO case definition
for a rabies exposure [13]. Vaccination of loosely defined exposures
has been reported in Bhutan, as well, where PEP is provided at no-
cost to patients [15]. These practices may jeopardize vaccination of
at-risk persons when PEP availability is limited, as occurred during
March 2018 when limited vaccine stocks were used to vaccinate 42
contacts around a human case and subsequently resulted in a
stockout at the Moramanga ARMC. Training to ensure that health
workers can effectively obtain 5  0.1 mL injections from 0.5 mL
vaccine vials would also enable more people to be treated with
potential to reduce costs and the risk of vaccine shortages. Rabies
control in the dog population would reduce the number of rabies
exposures and contacts with human and animal rabies cases, and
could therefore reduce the demand for PEP by over 40%.e utilization, provisioning of post-exposure prophylaxis, and estimation of
e.2018.11.011
8 M. Rajeev et al. / Vaccine xxx (xxxx) xxxSix times as many animal cases were laboratory confirmed dur-
ing our study period than in the previous 16 months (three animal
cases confirmed in the district). Given that between 2011 and
2015, an annual average of 60 rabies case were confirmed in the
country, our results suggest significant underreporting of animal
rabies both in the Moramanga district and nationally. Through
combined clinical and laboratory diagnosis, we were able to deter-
mine the rabies status of 40% of biting animals overall and a
higher proportion of animals investigated (70%). Clinic-based
triage of bite patients doubled the proportion of exposures we
were able to classify. While we did not detect many linked animal
cases (either source or secondary) through contact tracing as
demonstrated previously in Tanzania [16], we identified an addi-
tional 19 probable/confirmed exposures, 7 of whom reported to
the ARMC after the investigation. In Madagascar, when investiga-
tions of suspected human and laboratory confirmed animal cases
are conducted leads to the provision of PEP to people who have
been in contact with these animals or people. However, shifting
effort from these case investigations which focus on vaccinating
loosely-defined and likely low-risk contacts, towards routine
investigations of probable rabid animal bites to identify untreated
exposures, could be a more effective response to prevent human
deaths while increasing case detection as part of surveillance
[17,18].4.2. Strengths and limitations
We did not address the potential misclassification of rabies
cases through our investigations. Overall, 86% of samples from sus-
pected animals were confirmed positive; however, only 22 samples
were tested from the district during this period. Increased efforts
to laboratory confirm cases could improve confidence in clinical
diagnosis. In general, we believe that our case definition for prob-
able rabies was conservative and likely underestimates the true
proportion of rabies exposures (see Section 2, case definitions).
Moreover, we may have underestimated rabies exposures and
overestimated reporting as investigations were initiated only for
patients reporting to the ARMC. We likely missed individuals that
reported only to peripheral clinics or that did not report at all (that
were not linked to other ARMC patients). Bites by vaccinated dogs
also appear to be disproportionaly represented in the ARMC as
unpublished data from a recent vaccination campaign suggests
much lower dog vaccination coverage before the campaign was
implemented (5% pre-April 2018, M. Rajeev unpublished data).
During our study, only six patients bitten in the Moramanga Dis-
trict reported directly to IPM without referral, the nearest other
ARMC, suggesting that most bite victims in the district that seek
PEP are captured at the Moramanga ARMC.
We make several further simplifying assumptions in our esti-
mations of rabies burden in the Moramanga District and our
extrapolations to Madagascar. We did not incorporate risks due
to incomplete or delayed PEP or for severe exposures that did
not receive RIG. Since no deaths were reported from patients
who received delayed/incomplete PEP, PEP completion was high,
and severe exposures (i.e. deep wounds) uncommon, we believe
this will not have introduced major bias. We did not account for
vaccine availability and assumed that all patients that reported
to the ARMC received PEP. Although the clinic did not experience
PEP shortages during our study, in March 2018 the entire country
experienced a stockout, with no vaccine available at the Mora-
manga ARMC for two weeks. We also assumed uniform rabies inci-
dence and reporting across Madagascar. Given that only 31 of 114
districts have an ARMC, this likely underestimates the burden and
overestimates deaths averted. Data from other districts on bite
incidence, rabies exposures, health seeking behavior, and PEPPlease cite this article as: M. Rajeev, G. Edosoa, C. Hanitriniaina et al., Healthcar
human rabies burden in Madagascar, Vaccine, https://doi.org/10.1016/j.vaccinadherence and availability would improve our estimates and
understanding of rabies risk across Madagascar.
4.3. Wider context
The animal and patient characteristics described in our study
are similar to most other rabies endemic settings, with domestic
dogs responsible for the majority of animal bites and rabies cases
[19–21], rabies exposures disproportionately affecting children
under 15 years of age [12,22], patient demographics skewed male
[15,23,24], and high risk exposures (i.e. deep wounds or bites to
the head or neck) generally rare [25]. Unlike in some other rabies
endemic countries, the majority of patients reported washing the
wound with soap and water, which can greatly reduce risk of
transmission [26–29]. Our estimates of incidence of bite patients,
rabies exposures, and human rabies deaths were similar to those
from a wide range of endemic settings [19,21,22,29]. This is the
first estimate of rabies burden in Madagascar based on data speci-
fic to the country and is in line with the previous estimate of bur-
den for Madagascar using data from sub-Saharan Africa [1].
A higher proportion of suspect exposures sought (85%) and
completed PEP (90%) compared to other regions with endemic
rabies, where PEP is only available at a high cost to patients and
a lower proportion of rabies exposed persons receive PEP
[21,22,24,30,31]. Few other studies have described health-
seeking behavior and PEP adherence in settings where PEP is free;
however, in both Bhutan and Phnom Phen in Cambodia where PEP
is provided at no charge to patients, approximately 80–90% receive
and complete PEP [15,32]. Regardless of whether PEP is free, costs
to patients (in the case of free PEP, indirect costs) and limited geo-
graphical access seem to present the greatest barriers [17,22,33]. In
addition, awareness on the part of both patients and clinicians
responsible for referrals also contribute to bite victims not receiv-
ing PEP [34].
We were able to determine the rabies status for animals we
investigated to a comparable level as that reported in similar stud-
ies in Haiti and Tanzania [20,35]. Overall, approximately 20% of
animal bites were determined to be likely rabies exposures com-
pared to 13% in Haiti [20], 73% in Ethiopia [21], and 62% in Tanza-
nia [22]. This variation may be due to differences in dog
vaccination, as well as higher health seeking of people bitten by
non-rabid animals in free settings (higher levels of dog vaccination
coverage in Haiti and Tanzania; more costly PEP in Ethiopia and
Tanzania). Our results suggest that implementing recently devel-
oped integrated bite case management programs which use risk
assessments to prioritize PEP administration [17,34,36] and using
bite patients as sentinels for rabies surveillance [35] are feasible
and effective options to better manage PEP and improve surveil-
lance in Madagascar, especially as control in the dog population
is implemented.
4.4. Conclusions & recommendations
Our findings show that canine rabies is responsible for a high
incidence of human rabies exposures and preventable rabies
deaths in Madagascar, and accounts for a large proportion of the
demand for PEP. Given current successful ID administration of
PEP and vial sharing practices, adoption of the latest WHO recom-
mendations for PEP administration using the abridged 1-week ID
regimen could be implemented immediately in Madagascar to
reduce PEP costs. Shifting away from control strategies of reactive
culling to mass dog vaccination would further reduce both the high
costs of PEP and the burden of human rabies. Increasing access to
PEP and awareness for its need could also greatly reduce the bur-
den of human rabies, especially given its limited availability within
Madagascar. Nonetheless, the fact that where PEP is available, it ise utilization, provisioning of post-exposure prophylaxis, and estimation of
e.2018.11.011
M. Rajeev et al. / Vaccine xxx (xxxx) xxx 9provided to patients for free, appears to result in relatively high
health seeking and adherence in comparison to other low-
income settings. In general, more judicious use of PEP may be war-
ranted as access is expanded and vaccine use increases. Particu-
larly, if mass dog vaccination is implemented and risk of rabies
exposures decrease, integrated bite case management [36] could
be used to further reduce PEP demand while enhancing surveil-
lance of animal cases and identification of exposed persons
[20,35]. However, this would require improved integration of
activities and coordination between the health and veterinary sec-
tors. Given the push to eliminate deaths due to human rabies [4],
our results demonstrate that investing in rabies control as a public
good through providing free PEP can prevent needless human
deaths, and in combination with mass dog vaccination has the
potential to greatly reduce and eventually eliminate rabies from
Madagascar.
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